Welcome to our dedicated page for EBR SYS SEC filings (Ticker: EBRCZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
EBR Systems, Inc. filings document an emerging growth company’s financial updates, governance votes, and capital-structure changes. The company’s Form 8-K reports include preliminary operating results, commercial and clinical progress, annual and special meeting voting results, and amendments to its certificate of incorporation.
Proxy materials for EBRCZ describe director elections, equity plan matters, shareholder approvals, common stock proposals, CHESS Depositary Interests, and related governance procedures. The filing record also documents the company’s reverse stock split, security issuance ratifications, and recurring disclosure controls around unaudited preliminary financial information.
EBR Systems, Inc. reported the results of its 2026 annual stockholder meeting held via webcast. Stockholders elected Class II directors John McCutcheon and Bronwyn Evans to serve until the 2029 annual meeting.
They also approved adding 18,010,366 shares of common stock to the 2021 Equity Incentive Plan under its evergreen provision and ratified multiple option grants to directors and related entities. These grants include options valued at US$716,154 for John McCutcheon, US$160,000 for Allan Will, and several US$130,000 awards for other directors and their nominated entities, all under Australian Securities Exchange listing rules.
EBR Systems, Inc. furnished an update highlighting strong early commercial adoption of its WiSE wireless cardiac pacing system and preliminary Q1 2026 results. The company completed its 71st commercial implant, including 41 commercial patients in Q1 2026, more than double the prior quarter’s case count.
During Q1 2026, EBR signed 16 additional purchase agreements with target centres, bringing the total to 37, and expanded its implanter base to 55 trained physicians, with 22 trained in the quarter. The company also implemented a 1-for-10 reverse stock split of its common stock effective April 1, 2026, while changing its CDI conversion ratio to 10:1 without altering individual ownership ratios.
Management will discuss these commercial and clinical developments, along with preliminary unaudited Q1 2026 financial information, on an investor webinar scheduled for April 10, 2026 at 09:00am AEST. All financial figures remain preliminary and unaudited pending completion of the quarter-end close and review procedures.
EBR Systems, Inc. approved and implemented a 1-for-10 reverse stock split of its common stock, effective April 1, 2026 at 4:00 a.m. Eastern Time. Every 10 issued and outstanding shares will automatically convert into 1 share, with fractional shares rounded up to the nearest whole share.
The amendment does not change the number of authorized common shares or their par value. CHESS Depositary Interests will not be consolidated; instead, the CDI-to-share conversion ratio will shift from 1:1 to 10:1, with no anticipated change in CDI value apart from minor rounding effects.
On the ASX, March 30, 2026 (Australian time) will be the last trading day on a pre-split 1:1 basis, and March 31, 2026 will be the first trading day on a deferred settlement basis using the new 10:1 conversion ratio.
EBR Systems, Inc. is asking stockholders to vote at its 2026 virtual annual meeting on director elections and multiple equity compensation items. The meeting will be held online on May 7, 2026 (Australia) / May 6, 2026 (U.S.), with a record date of March 9, 2026.
Proposals include electing two Class II directors, approving an increase of 18,010,366 shares of Common Stock reserved under the 2021 Equity Incentive Plan via its 4% “evergreen” feature, and approving option grants to the CEO and other directors. If approved, the plan’s base share reserve would rise to 54,849,798 shares, with ASX Exception 13 treatment.
The proxy details how holders of Common Stock and CHESS Depositary Interests can vote or instruct CHESS Depositary Nominees, quorum and vote thresholds, ASX voting exclusions, and board/committee composition. It also notes a previously approved but not yet implemented reverse stock split in a range of 1-for-5 to 1-for-20, which would proportionately adjust share and CDI amounts when effected.
EBR Systems, Inc. President and CEO John McCutcheon exercised stock options to acquire 109,100 shares of common stock at an exercise price of $0.55 per share. The transaction converted previously granted options into directly held shares, with no open-market sale reported. Following the exercise, 109,100 common shares are shown as directly owned, and the related option grant originally covered 1,590,000 shares, vesting monthly beginning on June 29, 2024.
EBR Systems, Inc. is a U.S.-based medical device company focused on the WiSE CRT System, a leadless cardiac resynchronization therapy platform that paces the left ventricle using ultrasound energy instead of traditional leads.
On April 11, 2025, the FDA’s Center for Devices and Radiological Health approved the company’s premarket approval application for WiSE CRT for specific adult heart failure patients who need CRT but cannot receive or are high risk for conventional coronary sinus leads. As a condition of approval, EBR must run a long-term post-approval study following implanted patients for up to five years.
U.S. reimbursement is bolstered by CMS programs: WiSE received New Technology Add-On Payment and Transitional Pass-Through status starting October 1, 2025, with NTAP covering up to $41,145 per case based on an average selling price of $63,300. EBR is executing a phased U.S. commercial rollout, from soft launch to a Limited Market Release and planned full market release in the second half of 2026, while preparing for future launches in Australia, the U.K. and EU.
The company holds an extensive patent and trademark portfolio around WiSE CRT, but faces risks including dependence on single-source components, stringent global regulatory obligations, extensive post-market commitments, evolving reimbursement and healthcare reform, cybersecurity exposure, and the need to scale manufacturing, sales, and specialized talent to support growth.
EBR Systems, Inc. is asking stockholders to vote at a virtual Annual Meeting on May 7, 2026 (Australia) / May 6, 2026 (U.S.). The meeting agenda includes election of two directors and nine proposals, notably Proposal 2 to add 18,010,366 shares to the 2021 Equity Incentive Plan by operation of its “evergreen” provision. As of the record date, there were 450,435,794 shares outstanding. The Board has approved, but not yet implemented, a reverse stock split (ratios between 1-for-5 and 1-for-20) that will change CDI transmutation if effected prior to final adjustments. Proxy materials and the 2025 Form 10-K are available at the Company’s investor center.
EBR Systems, Inc. reported that stockholders approved all three proposals at a virtual special meeting held on March 11, 2026. Investors authorized a reverse stock split of the company’s common stock at a ratio between 1-for-5 and 1-for-20, to be implemented at the board’s discretion, with 233,231,110 votes in favor and 970,364 against.
Stockholders also ratified the prior issuance of 55,900,000 CHESS Depositary Interests (equivalent to 55,900,000 common shares) at an issue price of A$1.00 per CDI under ASX Listing Rule 7.4, and approved a potential adjournment of the meeting if additional proxy solicitations had been needed.